Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
6213 results
Cited 18 times since 2013 (1.5 per year) source: EuropePMC
International journal of cardiology, Volume 169, Issue 2, 8 2 2013, Pages 139-144 Postoperative arrhythmias in adults with congenital heart disease: incidence and risk factors. Koyak Z, Achterbergh RC, de Groot JR, Berger F, Koolbergen DR, Bouma BJ, Lagrand WK, Hazekamp MG, Blom NA, Mulder BJ
Background: Little is known about the clinical impact of arrhythmias after surgery for congenital heart disease (CHD) in adults. Therefore, we investigated the prevalence of in-hospital arrhythmias after CHD surgery and their impact on clinical outcome. Methods: This was a multicenter retrospective study and included adults who underwent congenital cardiac surgery between January 2009 and December 2011. Clinical events were defined as all cause mortality, heart failure (HF) requiring medical tre... Abstract
Cited 42 times since 2013 (3.6 per year) source: EuropePMC
International journal of cardiology, Volume 169, Issue 3, 7 1 2013, Pages 183-189 A cornerstone of heart failure treatment is not effective in experimental right ventricular failure. Borgdorff MA, Bartelds B, Dickinson MG, Steendijk P, Berger RM
Background: Right ventricular (RV) failure due to increased pressure load causes significant morbidity and mortality in patients with congenital heart diseases and pulmonary arterial hypertension. It is unknown whether renin-angiotensin-aldosterone-system (RAAS) inhibition (the cornerstone of left ventricular failure treatment) is effective in RV failure. We investigated the effects of combination treatment of aldosterone-blocker eplerenone+angiotensin II receptor blocker losartan (Ep/Lo) on RV... Abstract
Cited 14 times since 2013 (1.2 per year) source: EuropePMC
Journal of molecular and cellular cardiology, Volume 64, 5 1 2013, Pages 51-58 C57BL/6 NK cell gene complex is crucially involved in vascular remodeling. de Vries MR, Seghers L, van Bergen J, Peters HA, de Jong RC, Hamming JF, Toes RE, van Hinsbergh VW, Quax PH
Objective: NK cells are known to be involved in cardiovascular disease processes. One of these processes, vascular remodeling, may strongly differ between individuals and mouse strains such as the C57BL/6 and BALB/c. Moreover, C57BL/6 and BALB/c mice vary in immune responses and in the composition of their Natural Killer gene Complex (NKC). Here we study the role of NK cells, and in particular the C57BL/6 NKC in vascular remodeling and intimal hyperplasia formation. Methods and results: C57BL/6,... Abstract
Cited 16 times since 2013 (1.4 per year) source: EuropePMC
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, Volume 46, Issue 6, 4 1 2013, Pages 624-629 Results from craniocaudal carotid body tumor resection: should it be the standard surgical approach? Paridaans MP, van der Bogt KE, Jansen JC, Nyns EC, Wolterbeek R, van Baalen JM, Hamming JF
Objectives: To evaluate results after carotid body tumor (CBT) surgery using a novel dissection technique. Methods: A retrospective analysis of all operated CBT in the last 6 years was carried out and results were compared with the current literature and our previous series, which reported another 111 cases operated on until 2005. Results: Forty-five CBTs were removed in 41 (56% hereditary cases) patients (seven Shamblin I, 22 II, and 16 III). There were no cases of permanent cranial nerve injur... Abstract
Cited 35 times since 2013 (3 per year) source: EuropePMC
Journal of plastic, reconstructive & aesthetic surgery : JPRAS, Volume 66, Issue 12, 4 1 2013, Pages 1732-1740 Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. de Graaf M, Raphael MF, Breugem CC, Knol MJ, Bruijnzeel-Koomen CA, Kon M, Breur JM, Pasmans SG
Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH). However, several side effects have been reported. Atenolol, a hydrophilic selective beta-1 blocker, could be an alternative and associated with fewer side effects. Thirty consecutive patients with IH were treated with atenolol between June 2010 and May 2011. The therapeutic effect was judged by clinical assessment and quantified by using a visual analogue scale (VAS) a... Abstract
Cited 192 times since 2013 (16.3 per year) source: EuropePMC
European heart journal, Volume 34, Issue 45, 2 1 2013, Pages 3491-3500 Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ
Aim: Patients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients. Methods and results: In this multicentre, open-label, randomized controlled trial with blinded assessments, we compared losartan treatment with no additional treatment in operated and unoperated adults with Marfan syndrome. The primary endpoint... Abstract
Cited 11 times since 2013 (0.9 per year) source: EuropePMC
Pacing and clinical electrophysiology : PACE, Volume 37, Issue 1, 2 1 2013, Pages 25-34 Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry. Thijssen J, van den Akker van Marle ME, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van Erven L, Schalij MJ
Background: Although randomized trials have shown the beneficial effect on survival of an implantable cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, the purpose of this study was to assess the cost-effectiveness of primary prevention ICD implantation in the real world. Methods: Patients receiving primary prevention single-chamber or dual-chamber ICD implantation a... Abstract
Cited 32 times since 2013 (2.7 per year) source: EuropePMC
PloS one, Volume 8, Issue 9, 2 1 2013, Pages e72642 Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Lloyd SM, Stott DJ, de Craen AJ, Kearney PM, Sattar N, Perry I, Packard CJ, Briggs A, Marchbank L, Comber H, Jukema JW, Westendorp RG, Trompet S, Buckley BM, Ford I
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of pravastatin, demonstrated a 19% reduction in coronary outcomes (p=0.006) after a mean of 3.2 years, with no impact on stroke outcomes or all-cause mortality. However, there was a suggestion of increased cancer risk. Our aim is to determine the long-term benefits and safety of pravastatin treatment in older people using post-trial follow-up of the PROSPER participants. Methods: 5,804 (... Abstract
Cited 421 times since 2013 (35.7 per year) source: EuropePMC
The New England journal of medicine, Volume 369, Issue 15, 2 1 2013, Pages 1395-1405 Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J, Gras D, Krum H, Sogaard P, Holzmeister J, EchoCRT Study Group
Background: Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. Methods: We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or le... Abstract
Cited 31 times since 2013 (2.6 per year) source: EuropePMC
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 8, Issue 9, 1 1 2013, Pages 1190-1195 KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. Mellema WW, Dingemans AM, Thunnissen E, Snijders PJ, Derks J, Heideman DA, Van Suylen R, Smit EF
Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is thought to be related with dismal outcome for non-small-cell lung cancer (NSCLC) patients. The role of KRAS mutation as a predictor of response to chemotherapy for patients with metastatic NSCLC is poorly understood. Methods: From a retrospective database of two university hospitals, all patients with advanced, nonsquamous NSCLC treated with first-line platinum-containing chemotherapy were selected. Mutation analysis for K... Abstract
Cited 60 times since 2013 (5.1 per year) source: EuropePMC
Intensive care medicine, Volume 39, Issue 11, 31 5 2013, Pages 2011-2019 Safety and effects of two red blood cell transfusion strategies in pediatric cardiac surgery patients: a randomized controlled trial. de Gast-Bakker DH, de Wilde RB, Hazekamp MG, Sojak V, Zwaginga JJ, Wolterbeek R, de Jonge E, Gesink-van der Veer BJ
Objective: To investigate the safety and effects of a restrictive red blood cell (RBC) transfusion strategy in pediatric cardiac surgery patients. Design: Randomized controlled trial. Setting: Pediatric ICU in an academic tertiary care center, Leiden University Medical Center, Leiden, The Netherlands. Patients: One hundred seven patients with non-cyanotic congenital heart defects between 6 weeks and 6 years of age. One hundred three patients underwent corrective surgery on cardiopulmonary bypass... Abstract
Cited 4 times since 2013 (0.3 per year) source: EuropePMC
Revista espanola de cardiologia (English ed.), Volume 66, Issue 11, 31 5 2013, Pages 912-913 Usefulness of exercise test in cardiac resynchronization therapy follow-up. de Riva-Silva M, López Gil M, Fontenla-Cerezuela A, Salgado-Aranda R, Salguero-Bodes R, Arribas-Ynsaurriaga F
Cited 17 times since 2013 (1.4 per year) source: EuropePMC
Atherosclerosis, Volume 231, Issue 1, 31 5 2013, Pages 48-53 Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis. Willems S, Quax PH, de Borst GJ, de Vries JP, Moll FL, de Kleijn DP, Hoefer IE, Pasterkamp G
Objective: Soluble ST2 (sST2), a novel biomarker predictive for heart disease, has recently been shown associated with the progression of atherosclerotic disease in a mouse model. The present study was designed to assess sST2 plasma levels in patients scheduled for carotid endarterectomy and relate it with the occurrence of adverse cardiovascular events during follow-up. In addition, sST2 levels were associated to patient clinical data and atherosclerotic plaque characteristics. Methods and resu... Abstract
Cited 2422 times since 2013 (205.5 per year) source: EuropePMC
European heart journal, Volume 34, Issue 38, 30 5 2013, Pages 2949-3003 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, ESC Committee for Practice Guidelines, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL
Cited 1139 times since 2013 (96.6 per year) source: EuropePMC
European heart journal, Volume 34, Issue 39, 30 5 2013, Pages 3035-3087 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schächinger V, Scheen A, Schirmer H, Strömberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C, Xuereb RG
Cited 12 times since 2013 (1 per year) source: EuropePMC
Circulation journal : official journal of the Japanese Circulation Society, Volume 77, Issue 11, 29 5 2013, Pages 2793-2798 Clinical features differ substantially between Caucasian and Asian populations of Marfan syndrome. Franken R, den Hartog AW, van de Riet L, Timmermans J, Scholte AJ, van den Berg MP, de Waard V, Zwinderman AH, Groenink M, Yip JW, Mulder BJ
Background: Prevention of aortic dissection and sudden death in patients with Marfan syndrome (MFS) requires accurate diagnosis. MFS is diagnosed by the Ghent criteria, which are primarily based on clinical features of Caucasian MFS populations. We determined whether the Ghent criteria apply to Asian MFS populations. Methods and results: In this multicenter study, we included 255 adult MFS patients according to the Ghent criteria of 2010. Patients were excluded if they were neither Caucasian nor... Abstract
Cited 7 times since 2013 (0.6 per year) source: EuropePMC
Pediatric hematology and oncology, Volume 31, Issue 4, 29 5 2013, Pages 318-326 Leukapheresis in childhood acute leukemias: single-center experience. Yilmaz D, Karapinar B, Karadaş N, Duyu M, Yazici P, Ay Y, Balkan C, Aydinok Y, Kavakli K
Hyperleukocytosis in patients with leukemia is associated with early mortality, especially due to the pulmonary and neurological complications of leukostasis. The prompt use of leukapheresis may improve patients' survival in the initial treatment period. The medical records of all previously untreated acute leukemia patients were reviewed to determine whether there was hyperleukocytosis at presentation. This study summarizes a single-center experience of leukapheresis that was applied to 12... Abstract
Cited 75 times since 2013 (6.4 per year) source: EuropePMC
Journal of cardiovascular translational research, Volume 6, Issue 5, 28 4 2013, Pages 816-825 Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. Rodrigo SF, van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, Roelofs H, Al Younis I, Dibbets-Schneider P, Fibbe WE, Zwaginga JJ, Bax JJ, Schalij MJ, Beeres SL, Atsma DE
In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related t... Abstract
Cited 16 times since 2013 (1.4 per year) source: EuropePMC
Clinical research in cardiology : official journal of the German Cardiac Society, Volume 102, Issue 11, 23 4 2013, Pages 847-856 Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study. Hoefer IE, Sels JW, Jukema JW, Bergheanu S, Biessen E, McClellan E, Daemen M, Doevendans P, de Groot P, Hillaert M, Horsman S, Ilhan M, Kuiper J, Pijls N, Redekop K, van der Spek P, Stubbs A, van de Veer E, Waltenberger J, van Zonneveld AJ, Pasterkamp G
Biomarkers for primary or secondary risk prediction of cardiovascular disease (CVD) are urgently needed to improve individual treatment and clinical trial design. The vast majority of biomarker discovery studies has concentrated on plasma/serum as an easily accessible source. Although numerous markers have been identified, their added predictive value on top of traditional risk factors has been limited, as the biological specimen does not specifically reflect expression profiles related with CVD... Abstract
Multimedia manual of cardiothoracic surgery : MMCTS, Volume 2013, 23 4 2013, Pages mmt009 The Bex-Nikaidoh operation for dextro-transposition of the great arteries with a ventricular septal defect and pulmonary stenosis using an 'oversized' conduit. Chernogrivov AE, Bazylev VV, Chernogrivov IE, Kalinicheva J, Paramonova T, Nevvazhay T
We report a case of a 4-month-old infant with dextro (d)-transposition of the great arteries, ventricular septal defect (VSD) and left ventricular outflow tract obstruction previously palliated with a systemic-to-pulmonary shunt. He underwent repair by aortic root translocation with an arterial switch procedure and coronary artery reimplantation (modified Bex-Nikaidoh operation). This case demonstrates that aortic translocation results in a more normal anatomic repair compared with the Rastelli... Abstract